BSX · Boston Scientific Corp · Financials
$42.22
+0.18 (+0.42%)
At close · Oct 9
Return incl. dividend (before tax)
Market Cap
$61.07B
Shares
1.45B
Volume · Oct 9
4.88M
Avg daily vol (3M)
19.76M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$20.07B
+19.9%
FY2025
Net Income
$2.89B
+56.7%
FY2025
Gross Margin
69.01%
+0.4pp
FY2025
Operating Margin
18%
+2.5pp
FY2025
Diluted EPS
$1.94
+55.2%
FY2025
Operating Cash Flow
$4.53B
+32%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $21B | $20.07B | $16.75B | $14.24B | $12.68B | $11.89BG | $9.91B | $10.74B | $9.82B | $9.05B | $9.08B | $8.07B | $7.46B | $7.07B | $6.96B | $7.62B | $7.81B | $8.19B | $8.05B | $8.36B | |
| — | $6.32B | $6.22B | $5.26B | $4.35B | $3.96B | $3.71B | $3.47B | $3.12B | $2.81B | $2.59B | $2.42B | $2.17B | $2.21B | $2.17B | $2.35B | $2.66B | $2.6B | $2.58B | $2.47B | $2.34B | |
| — | $14.68B | $13.85B | $11.49B | $9.9B | $8.73B | $8.18B | $6.45B | $7.62B | $7.01B | $6.46B | $5.96B | $5.3B | $5.17B | $4.97B | $4.9B | $4.96B | $5.21B | $5.61B | $5.58B | $6.02B | |
| — | — | 69.01% | 68.61% | 69.49% | 68.81% | 68.78% | 65.05% | 70.98% | 71.37% | 71.34% | 65.69% | 65.74% | 69.28% | 70.26% | 70.42% | 65.11% | 66.71% | 68.54% | 69.33% | 71.98% | |
| — | $2.15B | $2.05B | $1.62B | $1.41B | $1.32B | $1.2B | $1.14B | $1.17B | $1.11B | $997M | $920M | $876M | $817M | $861M | $886M | $895M | $939M | $1.04B | $1.01B | $1.09B | |
| — | $7.16B | $6.89B | $5.98B | $5.19B | $4.52B | $4.36B | $3.79B | $3.94B | $3.57B | $3.29B | $3.1B | $2.87B | $2.9B | $2.67B | $2.54B | $2.49B | $2.58B | $2.64B | $2.59B | $2.91B | |
| — | $918M | $897M | $856M | $828M | $803M | $741M | $789M | $699M | $599M | $565M | $545M | $495M | $438M | $410M | $395M | $421M | $513M | $511M | $543M | $620M | |
| — | $1.41B | $1.37B | $1.27B | $1.2B | $1.14B | $1.09B | $1.12B | $1.01B | $894M | $844M | $815M | $769M | $725M | $689M | $683M | $717M | $816M | $834M | $864M | $918M | |
| — | $19M | $101M | $16M | $69M | $24M | $40M | $52M | $38M | $36M | $37M | $28M | $26M | $69M | $101M | $136M | $89M | $116M | $63M | $78M | $176M | |
| — | $10.53B | $10.24B | $8.89B | $7.55B | $7.08B | $6.98B | $6.53B | $6.1B | $5.5B | $5.17B | $5.52B | $5.59B | $5.47B | $4.85B | $8.77B | $4.06B | $5.86B | $6.51B | $7.09B | $6.03B | |
| — | $4.15B | $3.61B | $2.6B | $2.34B | $1.65B | $1.2B | -$80M | $1.52B | $1.51B | $1.29B | $447M | -$283M | -$301M | $120M | -$3.87B | $904M | -$656M | -$894M | -$1.51B | -$14M | |
| — | — | 18% | 15.54% | 16.45% | 13% | 10.09% | -0.81% | 14.14% | 15.33% | 14.2% | 4.93% | -3.51% | -4.03% | 1.7% | -55.59% | 11.86% | -8.4% | -10.92% | -18.7% | -0.17% | |
| — | $5.57B | $4.98B | $3.87B | $3.54B | $2.79B | $2.29B | $1.04B | $2.53B | $2.4B | $2.13B | $1.26B | $486M | $424M | $809M | -$3.19B | $1.62B | $160M | -$60M | -$641M | $904M | |
| — | $363M | $349M | $305M | $265M | $470M | $341M | $361M | $473M | $241M | $229M | $233M | $284M | $216M | $324M | $261M | $281M | $393M | $407M | $468M | $570M | |
| — | -$291M | -$228M | -$321M | -$358M | -$508M | -$123M | $1M | -$831M | -$85M | -$353M | -$270M | -$367M | -$208M | -$343M | -$239M | -$262M | -$407M | -$414M | -$526M | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $6M | $10M | — | |
| — | $94M | $139M | -$79M | -$59M | -$1M | $250M | $333M | -$30M | $155M | -$92M | -$21M | -$9M | $27M | -$9M | $37M | $27M | -$12M | $9M | $52M | — | |
| — | $3.86B | $3.39B | $2.28B | $1.99B | $1.14B | $1.08B | -$79M | $687M | $1.42B | $933M | $177M | -$650M | -$509M | -$223M | -$4.11B | $642M | -$1.06B | -$1.31B | -$2.03B | -$569M | |
| — | $193M | $493M | $436M | $393M | $443M | $36M | $2M | -$4.01B | -$249M | $828M | -$170M | -$411M | -$390M | -$102M | -$39M | $201M | $2M | -$283M | $5M | -$74M | |
| — | $3.67B | $2.89B | $1.85B | $1.59B | $698M | $1.04B | -$82M | $4.7B | $1.67B | $104M | $347M | -$239M | -$119M | -$121M | -$4.07B | $441M | -$1.07B | -$1.03B | -$2.04B | -$495M | |
| — | — | 14.41% | 11.02% | 11.18% | 5.5% | 8.76% | -0.83% | 43.78% | 17.01% | 1.15% | 3.82% | -2.96% | -1.59% | -1.71% | -58.47% | 5.79% | -13.64% | -12.52% | -25.29% | -5.92% | |
| — | -$6M | -$6M | -$8M | -$1M | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $3.68B | $2.9B | $1.85B | $1.57B | $642M | $985M | -$115M | $4.7B | $1.67B | — | — | — | — | — | — | — | — | — | — | — | |
| — | $4.09B | $2.01B | $2.08B | $1.37B | $704M | $1.1B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| USD/shares | — | $2.48 | $1.96 | $1.26 | $1.08 | $0.45 | $0.69 | -$0.08 | $3.38 | $1.21 | $0.08 | $0.26 | -$0.18 | -$0.09 | -$0.09 | -$2.89 | $0.29 | -$0.70 | -$0.68 | -$1.36 | -$0.33 |
| USD/shares | $3.28 – $3.32* | $2.47 | $1.94 | $1.25G | $1.07G | $0.45G | $0.69 | -$0.08 | $3.33 | $1.19 | $0.08 | $0.25 | -$0.18 | -$0.09 | -$0.09 | -$2.89 | $0.29 | -$0.70 | -$0.68 | -$1.36 | -$0.33 |
| shares | — | — | 1.48B | 1.47B | 1.45B | 1.43B | 1.42B | 1.42B | 1.39B | 1.38B | 1.37B | 1.36B | 1.34B | 1.32B | 1.34B | 1.41B | 1.51B | 1.52B | 1.51B | 1.5B | 1.49B |
| shares | — | — | 1.49B | 1.49B | 1.46B | 1.44B | 1.43B | 1.42B | 1.41B | 1.4B | 1.39B | 1.38B | 1.34B | 1.32B | 1.34B | 1.41B | 1.52B | 1.52B | 1.51B | 1.5B | 1.49B |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2011–FY2024: $2.25B in buybacks, $166M in dividends.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current debt and lease obligations | 2026-06-30 | USD 1,709,000,000 | 10-Q filed 2026-08-03 |
| Noncurrent long-term debt and lease obligations | 2026-06-30 | USD 10,915,000,000 | 10-Q filed 2026-08-03 |
7 filing observations remain unmatched and are excluded from instrument histories.
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
2 filings have incomplete source or extraction coverage. Verified observations are shown; missing observations do not establish that debt was unchanged.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
3.40×
Peer median 3.50×
EV/EBIT
17.20×
Peer median 19.66×
P/E (TTM)
17.06×
Peer median 27.08×
Peer medians compare against the 15 similar-size Medical Devices companies (of 149 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cardiovascular | $13,250,000,000 | $10,755,000,000 | $8,819,000,000 | $7,831,000,000 | $7,242,000,000 | $5,866,000,000 | $4,208,000,000 | $3,777,000,000 |
| Medsurg | $6,824,000,000 | $5,993,000,000 | $5,422,000,000 | $4,911,000,000 | $4,633,000,000 | $3,827,000,000 | $3,307,000,000 | $3,007,000,000 |
| BSX Reportable Segments | — | — | — | — | — | $9,694,000,000 | $10,654,000,000 | — |
| Rhythm and Neuro | — | — | — | — | — | $2,752,000,000 | $3,140,000,000 | $3,041,000,000 |
| All Other Segments | — | — | — | — | — | — | $81,000,000 | — |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $12,864,000,000 | $10,210,000,000 | $8,425,000,000 | $7,632,000,000 | $6,911,000,000 | $5,701,000,000 | $6,167,000,000 | $5,538,000,000 |
| Non Us | $7,210,000,000 | $6,538,000,000 | $5,816,000,000 | $5,111,000,000 | $4,978,000,000 | $4,212,000,000 | $4,569,000,000 | $4,286,000,000 |
| EMEA | $3,451,000,000 | $3,228,000,000 | $2,856,000,000 | $2,526,000,000 | $2,518,000,000 | $2,097,000,000 | $2,264,000,000 | $2,176,000,000 |
| Asia Pacific | $3,080,000,000 | $2,686,000,000 | $2,400,000,000 | $2,116,000,000 | $2,070,000,000 | $1,781,000,000 | $1,898,000,000 | $1,727,000,000 |
| Emerging Markets | $2,985,000,000 | $2,680,000,000 | $2,310,000,000 | $1,968,000,000 | $1,656,000,000 | $1,138,000,000 | $1,282,000,000 | $1,097,000,000 |
| Latin America and Canada | $678,000,000 | $624,000,000 | $560,000,000 | $469,000,000 | $386,000,000 | $307,000,000 | $395,000,000 | $383,000,000 |
| US Excluding Other Net Sales | — | $10,210,000,000 | $8,425,000,000 | $7,632,000,000 | $6,901,000,000 | $5,508,000,000 | — | — |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Interventional Cardiology Vascular Therapies | $4,639,000,000 | $4,199,000,000 | $3,791,000,000 | — | — | — | — | — |
| Electrophysiology EP | $3,325,000,000 | $1,904,000,000 | $800,000,000 | $585,000,000 | $365,000,000 | $287,000,000 | $329,000,000 | $311,000,000 |
| Global Endoscopy Endo Reporting Unit | $2,916,000,000 | $2,687,000,000 | $2,482,000,000 | $2,221,000,000 | $2,141,000,000 | $1,780,000,000 | $1,894,000,000 | $1,762,000,000 |
| Global Urology and Pelvic Health Reporting Unit | $2,709,000,000 | $2,200,000,000 | $1,964,000,000 | $1,773,000,000 | $1,583,000,000 | $1,286,000,000 | $1,413,000,000 | $1,245,000,000 |
| Cardiac Rhythm Management | $2,332,000,000 | $2,279,000,000 | $2,218,000,000 | $2,100,000,000 | $2,019,000,000 | $1,704,000,000 | $1,939,000,000 | $1,951,000,000 |
| Watchman | $1,958,000,000 | $1,516,000,000 | $1,274,000,000 | $1,019,000,000 | $829,000,000 | $324,000,000 | — | — |
| Global Neuromodulation NM Reporting Unit | $1,199,000,000 | $1,106,000,000 | $976,000,000 | $917,000,000 | $909,000,000 | $761,000,000 | $873,000,000 | $779,000,000 |
| Interventional Oncology Embolization | $996,000,000 | $856,000,000 | $736,000,000 | — | — | — | — | — |
| Global Cardiology Reporting Unit | — | — | — | $5,932,000,000 | $5,422,000,000 | $4,290,000,000 | — | — |
| Global Interventional Cardiology IC Reporting Unit | — | — | — | — | $3,038,000,000 | $2,299,000,000 | $2,816,000,000 | $2,590,000,000 |
| Global Peripheral Interventions Pi Reporting Unit | — | — | — | $1,899,000,000 | $1,820,000,000 | $1,577,000,000 | $1,392,000,000 | $1,187,000,000 |
| Interventional Cardiology Therapies | — | — | — | $2,228,000,000 | $2,209,000,000 | $1,975,000,000 | — | — |
| Other | — | — | — | -$60,000,000 | $13,000,000 | $219,000,000 | $81,000,000 | — |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|
| Total Allocated To Reportable Segments | $3,737,000,000 | $3,412,000,000 | $2,198,000,000 | $3,007,000,000 | $2,875,000,000 | $2,509,000,000 |
| Other | -$60,000,000 | $4,000,000 | $143,000,000 | $56,000,000 | — | — |
| Cardiovascular | — | — | — | $1,137,000,000 | $1,117,000,000 | $988,000,000 |
| Medsurg | — | — | — | $1,204,000,000 | $1,102,000,000 | $984,000,000 |
| Rhythm and Neuro | — | — | — | $666,000,000 | $655,000,000 | $537,000,000 |
Operating Margin by Segment (%)
| Component | FY2019 | FY2018 |
|---|---|---|
| Cardiovascular | 27% | 29.6% |
| Medsurg | 36.4% | 36.6% |
| Rhythm and Neuro | 21.2% | 21.5% |
Key facts
CIK
885725
CUSIP
101137107
13F (30d)
77 filings
62 filers
Visit website
Investor relations